Sun Pharmaceutical Industries Ltd Share Price

Pharmaceuticals

NSE: SUNPHARMA Large Cap ISIN: INE044A01036

As on 13 June 2026 at 02:22 IST

₹1,798.30

+ 4.10

(0.23%)

Sell Buy

Sun Pharma Q1 FY26 Results::

Net profit after tax for the period declined 20% to ₹2,279 crores in Q1 FY26, from ₹2,836 crores in Q1 FY25. Total income for the quarter increased 9% year-on-year to ₹14,316 crores from ₹13,185 crores.

About Sun Pharmaceutical Industries Ltd

Over 1 Month

-4.19%

Over 6 Months

-0.72%

Over 1 Year

6.13%

Over 3 Years

82.07%

Sun Pharmaceutical Industries Ltd Summary

Close ₹1,794.20

Open ₹1,780

High ₹1,805

Low ₹1,778.70

Volume 18,58,093

Net Turnover (in Cr) ₹333.44

52Wk High ₹1,916.60

52Wk Low ₹1,548

52Wk High / Low

1,548

1,916.60

Sun Pharmaceutical Industries Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹4,30,488.68

EPS (TTM) 12.51

Book Value (BV) 93.24

Div. Yield 0.89 %

P/E (TTM) 164.16

Price/Book Value 19.24

Delivery % 60.52 %

Face Value 1

Key Ratios

PE Ratio 97.22

PB Ratio 17.11

EV to Sales 18.55

PEG Ratio 1.95

ROA 11.86

ROE 17.83

Debt-Equity 0.47

Net Profit Margin 18.62

Operating Profit Margin 31.13

Sun Pharmaceutical Industries Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	54,729.01	49,887.17	44,520.20	39,729.96	34,357.31
Total Expenses	40,299.03	38,304.96	34,940.32	30,681.82	27,251.80
Profit Before Tax	13,752.13	11,087.89	9,408.43	4,481.32	2,799.37
Profit After Tax	10,980.10	9,648.44	8,560.84	3,405.82	2,284.68
Operating Profit After Depreciation	14,661.34	11,820.68	9,751.88	9,175.49	7,246.94

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	27,995.90	27,494.30	28,075.25	23,154.45	22,183.29
Total Non Current Assets	39,506.52	42,066.54	40,881.65	34,943.17	37,224.65
Total Current Assets	52,594.06	43,433.11	39,861.94	34,864.60	30,442.08
Total Assets	92,100.58	85,499.65	80,743.59	69,807.77	67,666.73
Total Shareholder's Fund	72,218.02	63,666.75	55,995.38	48,011.22	46,462.78

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	14,072.09	12,134.98	4,959.33	8,984.54	6,170.37
Net Cash Used In Investing Activities	-5,183.15	-762.90	-7,219.92	-5,555.86	406.53
Net Cash Used In Financing Activities	-7,905.82	-6,710.16	2,376.07	-5,193.46	-5,980.48

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	23,627.30	20,828.65	21,141.43	16,782.86	14,308.12
Total Expenses	18,596.73	17,159.98	16,462.59	14,655.47	13,362.99
Profit Before Tax	5,030.57	3,449.65	1,741.05	306.86	855.57
Profit After Tax	4,282.62	2,858.18	1,690.72	-99.99	842.40
Operating Profit After Depreciation	5,923.78	4,452.75	5,151.02	2,515.49	1,212.65

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	7,364.36	8,114.61	9,235.71	10,182.48	10,299.97
Total Non Current Assets	24,551.47	26,152.25	24,543.74	31,061.73	31,004.71
Total Current Assets	18,721.98	14,912.54	16,443.75	9,703.75	12,730.08
Total Assets	43,273.45	41,064.79	40,987.49	40,765.48	43,734.79
Total Shareholder's Fund	24,339.85	23,694.40	23,748.36	24,587.95	26,938.47

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	4,198.77	-292.42	507.08	7,636.36	-416.51
Net Cash Used In Investing Activities	-202.03	-265.35	-685.64	-2,697.04	1,452.47
Net Cash Used In Financing Activities	-3,831.18	473.95	169.31	-4,870.85	-999.73

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	14,611.79	15,520.54	14,478.31	13,851.40	12,958.84
Total Expenses	10,657.59	10,572.05	9,951.26	9,549.74	9,242.75
Profit Before Tax	3,551.34	4,227.16	4,167.61	3,172.77	3,254.35
Profit After Tax	2,723.72	3,401.09	3,137.09	2,302.62	2,160.64
Operating Profit after Depreciation	4,412.70	5,527.33	4,996.97	4,766.12	4,328.96

Particulars (in ₹ Cr.)	2026-03	2025-12	2025-09	2025-06	2025-03
Total Revenue	4,923.88	5,687.77	4,548.11	5,594.88	7,179.45
Total Expenses	3,594.91	3,929.17	3,364.52	3,685.35	4,120
Profit Before Tax	849.01	1,097.10	671.75	1,176.26	2,653.76
Profit After Tax	608.70	705.44	564.22	745.06	2,041.97
Operating Profit after Depreciation	1,391.90	1,938.50	1,256.38	2,013.24	3,191.58

Sun Pharmaceutical Industries Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,780.27

S2 1,766.33

S3 1,753.97

Pivot 1,792.63

R1 1,806.57

R2 1,818.93

R3 1,832.87

Moving Average

20 SMA 1,827.81

50 SMA 1,776.75

100 SMA 1,747.92

200 SMA 1,722.10

Sun Pharmaceutical Industries Ltd Corporate Actions

Sun Pharmaceutical Industries Ltd

₹11.0/Share

Announcement Date 05 Feb 2026

Record Date 05 Feb 2026

Div Yield 1100%

AGM Date: 31 Aug 2021

AGM 31/08/2021 As per letter attached. (As Per BSE Announcement Dated on 04.08.2021) As per letter attached. Chairman Speech at the 29th Annual General Meeting held on 31 August 2021 (As Per BSE Announcement Dated on 8/31/2021 7:57:07 AM) Sun Pharmaceutical Industries Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As per BSE Announcement Dated on 2/9/2021)

AGM Date: 29 Aug 2022

AGM 29/08/2022 This is to inform you that the 30th Annual General Meeting of the Company would be held on Monday, August 29, 2022 at 03:00 p.m. IST through Video Conferencing/ Other Audio-Visual Means. (As Per BSE Announcement Dated on 02.08.2022) Attached (As Per BSE Announcement Dated on 06/08/2022) Proceedings of 30th Annual General Meeting of Sun Pharmaceutical Industries Limited (As Per BSE Announcement Dated 29.08.2022) Pursuant to Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the following, with respect to 30th AGM of the Company held on August 29, 2022 at 3:00 p.m. IST by Video Conferencing. 1. Voting results as Annexure A 2. Scrutinizer's Consolidated Report as Annexure B All the resolutions set out in the Notice of the AGM were approved with the requisite majority. Sun Pharmaceutical Industries Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 30/08/2022)

AGM Date: 28 Aug 2023

This is to inform you that the 31st AGM of the members of Sun Pharmaceutical Industries Limited will be held on Monday, August 28, 2023 at 3.00 p.m. IST through Video Conferencing/ Other Audio-Visual Means. The Annual Report and the Notice of the AGM for FY2022-23, will be submitted to the stock exchanges and will be sent to the shareholders of the Company in due course. Pursuant to Regulation 34 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Report for the financial year 2022-23 including the Notice of Thirty-first Annual General Meeting ('31st AGM') of the Company. The 31st AGM of the members of Sun Pharmaceutical Industries Limited will be held on Monday, August 28, 2023 at 3:00 p.m. IST through Video Conferencing/ Other Audio-Visual Means. The Cut-off date for the purpose of determining the Members eligible to vote on the resolutions set out in the Notice of 31st AGM is Monday, August 21, 2023. The Remote e-voting period begins on Thursday, August 24, 2023 at 09:00 a.m. IST and ends on Sunday, August 27, 2023 at 05:00 p.m. IST. (As Per BSE Announcement dated on 27.07.2023) Please find enclosed herewith the speech delivered at the 31st Annual General Meeting held on August 28, 2023. Proceedings of 31st AGM of the Company is attached. (As per BSE Announcement Dated on 28/08/2023) Voting Results and Scrutinizer''s Consolidated Report of the 31st Annual General Meeting of the Company held on August 28, 2023 are attached. (As per BSE Announcement Dated on 29/08/2023)

AGM Date: 05 Aug 2024

AGM 05/08/2024 Intimation of 32nd Annual General Meeting and Connected Matters (As Per BSE Announcement dated on 19.06.2024) Intimation regarding Newspaper Publication for Notice of 32nd Annual General Meeting. (As Per BSE Announcement dated on 09.07.2024) Outcome of 32nd Annual General Meeting (As Per BSE Announcement Dated on: 05/08/2024) Scrutinizer''s Consolidated Report and Voting Results for 32nd AGM (As per BSE Announcement Dated on 06/08/2024)

AGM Date: 31 Jul 2025

The 33 rd Annual General Meeting ('AGM') of the Company will be held on Thursday, 31 July 2025,at 4:00 P.M. IST through Videoconferencing. The Notice of the AGM and the Annual Report will be released in due course. Notice of 33rd Annual General Meeting including Annual Report for FY 2024-25 (As per BSE Announcement Dated on 04/07/2025) Outcome and proceedings of the 33rd AGM of Sun Pharmaceutical Industries Limited held on 31 July 2025 (As Per BSE Announcement Dated on: 31/07/2025)

Sun Pharmaceutical Industries Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Divis Laboratories Ltd	₹6,651.25	₹1,76,569.79
Torrent Pharmaceuticals Ltd	₹4,570	₹1,54,669.57
Cipla Ltd	₹1,383	₹1,11,725.01
Zydus Lifesciences Ltd	₹1,105.65	₹1,11,254.26
Dr Reddys Laboratories Ltd	₹1,275.05	₹1,06,424.48

Sun Pharmaceutical Industries Ltd Top Mutal Funds Invested

Fund Name	AUM
ICICI Pru Value Fund	4.72%
ICICI Pru Equity & Debt Fund	4.16%
ICICI Pru India Opportunities Fund	3.68%
Nippon India Large Cap Fund	2.80%
ICICI Pru Large Cap Fund	2.65%

Sun Pharmaceutical Industries Ltd News

Sun Pharmaceutical Industries Ltd drops for fifth straight session

Sun Pharmaceutical Industries Ltd is quoting at Rs 1774.1, down 0.81% on the day as on 13:19 IST on the NSE. The stock jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.

04 Jun 2026, 01:35 pm

Board of Sun Pharmaceuticals Industries recommends final dividend

Of Rs 5 per share

23 May 2026, 10:24 am

Sun Pharma Q4 PAT jumps 26% YoY to Rs 2,714 cr

Sun Pharmaceutical Industries has reported 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago.

22 May 2026, 05:47 pm

Sun Pharmaceuticals Industries to declare Quarterly Results

On 22 May 2026

12 May 2026, 12:38 pm

Sun Pharmaceutical receives credit ratings from CRISIL and ICRA

07 May 2026, 07:29 pm

Sun Pharmaceutical Industries Ltd Stock Analysis

Annual revenue for Sun Pharmaceutical Industries Ltd increased by 13.44% to ₹23,627.30 crore in FY 2025 from ₹20,828.65 crore in FY 2024.
Annual Net Profit for Sun Pharmaceutical Industries Ltd increased by 49.84% to ₹4,282.62 crore in FY 2025 from ₹2,858.18 crore in FY 2024.
Promoter Shareholding in Sun Pharmaceutical Industries Ltd remains unchanged by 0.00% in the most recent quarter, from 54.48% in December 2025 to 54.48% in March 2026.
Sun Pharmaceutical Industries Ltd delivered a 1-year return of 6.13% compared to the Nifty 50, which provided a return of -7.87% as of the last trading session.
Sun Pharmaceutical Industries Ltd share price moved up by 0.23% from its previous close of INR ₹1,794.20. The latest Sun Pharmaceutical Industries Ltd share price is INR ₹1,798.30.
Sun Pharmaceutical Industries Ltd share price today has been at a low of 1,792.50 and a high of 1,807. Over the past 52 weeks, the Sun Pharmaceutical Industries Ltd share price has seen a low of 1,548 and a high of 1,916.60.

About Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd is commonly known as Sun Pharma. It is a leading player in the pharmaceutical sector. Headquartered in Mumbai, Maharashtra, the company specializes in manufacturing and marketing formulations and active pharmaceutical ingredients (APIs). The company was founded in 1983 and it has been in business for a long time. This showcases their strong and consistent presence in the industry. The main registered office is located in Sun Pharma Advanced Research Centre, Vadodra, Gujarat. Meanwhile, the registrar office is at L.B.S. Marg, Vikroli, Mumbai. These places serve as a central hub for its operations and strategic planning.
The main promoter of Sun Pharma is Dilip Shanghvi. He has been instrumental in steering the company towards success. Under his leadership, Sun Pharma has grown to become one of the largest pharmaceutical companies in the world. Many other managerial promoters have contributed to the success of the company, including Sudhir V Valia, Rama Bijapurkar, Aalok D Shanghvi, Rolf Hoffmann and Sailesh T Desai.
The main products offered by the company include branded generics and over the counter (OTC) medications. These products cover a broad spectrum of chronic and acute therapies. This includes cardiology, neurology and oncology. Sun Pharma’s stock is highly regarded in the pharmaceutical sector, reflecting its financial health. The company is one of the largest players in the industry, with a huge market share and capitalization. This dominant position is a testament to the company’s effective strategies and competitive edge. The promoter shareholding also stands at a significant percentage. As a result, it indicates a strong commitment towards the company’s growth. Overall, Sun Pharma’s market position and strong leadership make it a prominent player in its sector, with a promising future ahead.

Sun Pharma’s Journey - Years of Growth and Success

The journey of Sun Pharmaceutical Industries Ltd has been marked by years of growth and success. This remarkable story began in 1983 when the company was established. Over the past decades, this pharmaceutical giant has carved out a path of continuous expansion and achievement.
At the outset, Sun Pharma had a modest beginning with just five products. However, the company’s founders held a vision of growth and innovation. So, year after year, they reached new milestones and conquered fresh territories. As a result, the company’s product portfolio expanded, strengthening its market presence.
In 1997, Sun Pharma was listed on the stock exchange. This was a significant step for them. It was seen as a testament to the company’s growing stature and financial health. As a result, the company was able to raise more capital. This allowed for further expansion and development of new products. As the years progressed, Sun Pharma’s footprint expanded beyond Indian borders. They entered international markets. So, their products were available to patients worldwide. This global expansion was achieved through organic growth and strategic acquisitions.
Sun Pharma reached one of the most significant milestones in 2014. This was when they acquired Ranbaxy Laboratories. The acquisition was hailed as a game-changer in the pharmaceutical industry. This is because it solidified the company’s position as a leading player in the global pharmaceutical market. Sun Pharma has implemented strict quality control measures in its manufacturing process. Their commitment to quality has been appreciated by regulatory bodies worldwide. As a result, the company has earned the trust of patients and healthcare professionals.
The success of Sun Pharma can be attributed to several factors. Their management team has helped create a clear vision and a culture of innovation. As a result, the company has been able to meet the changing needs of patients and healthcare systems. Financial success has also been a hallmark of Sun Pharma’s journey. Year after year, the company reports strong financial results. So, its stock has been considered a favourite among investors. This is because shareholders can potentially benefit from huge returns.
However, the journey has not been without challenges. The company has faced regulatory hurdles, patent disputes, and market competition. But each challenge has been met with determination and innovative solutions. This resilience has helped the company emerge stronger from each setback.
As Sun Pharma looks to the future, it is exploring new horizons. The company is investing in cutting-edge technologies and therapies. It is also looking to expand its presence in speciality and complex generics. As a result, Sun Pharma continues to uphold its commitment to making quality healthcare accessible to all.
Sun Pharma's journey impacts more than just business success. Its products touch and improve lives. The company also creates employment opportunities for thousands of people. Sun Pharma has maintained a strong focus on research and development throughout its journey. This has resulted in the creation of innovative and effective pharmaceutical products. As a result, the company's commitment to quality and innovation has been recognized globally.